| 4.35 -0.16 (-3.55%) | 07-28 10:42 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.63  |
1-year : | 6.51 |
| Resists | First : | 4.82 |
Second : | 5.57 |
| Pivot price | 4.68 |
|||
| Supports | First : | 3.59 |
Second : | 2.99 |
| MAs | MA(5) : | 4.4 |
MA(20) : | 4.67 |
| MA(100) : | 3.84 |
MA(250) : | 2.62 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 13.4 |
D(3) : | 14.6 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 6.94 | Low : | 1.21 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ZNTL ] has closed above bottom band by 4.0%. Bollinger Bands are 34% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.65 - 4.68 | 4.68 - 4.71 |
| Low: | 4.29 - 4.32 | 4.32 - 4.35 |
| Close: | 4.46 - 4.51 | 4.51 - 4.55 |
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Mon, 27 Jul 2026
Zentalis Pharmaceuticals Market Sentiment - Benzinga España
Sat, 25 Jul 2026
Zentalis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ZNTL - TradingView
Sat, 25 Jul 2026
Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence - TradingKey
Mon, 20 Jul 2026
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? - Yahoo! Finance Canada
Mon, 20 Jul 2026
What date does Zentalis Pharmaceuticals's (ZNTL) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
Sun, 19 Jul 2026
ZNTL Jumps As Mizuho Targets Upside On Cancer Drug - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 22.8 (%) |
| Held by Institutions | 61.9 (%) |
| Shares Short | 6,150 (K) |
| Shares Short P.Month | 4,980 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.9 % |
| Return on Equity (ttm) | -52 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -126 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -2.43 |
| PEG Ratio | 0 |
| Price to Book value | 1.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|